Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG-PET/CT.
Sara FernándezLaura CerecedaEva DíazSasha FigueroaLaura RegueraVictoria MenéndezJosé L SolórzanoCarlos MontalbánMónica EstévezJuan Fernando GarcíaPublished in: EJHaem (2023)
The value of circulating tumor DNA (ctDNA) as a biomarker of disease activity in classic Hodgkin lymphoma (cHL) patients has not yet been well established. By profiling primary tumors and ctDNA, we identified common variants between primary tumors and longitudinal plasma samples in most of the cases, confirming high spatial and temporal heterogeneity. Although ctDNA analyses mirrored HRS cell genetics overall, the prevalence of variants shows that none of them can be used as a single biomarker. Conversely, the estimation of hGE/mL, based on measures of total ctDNA, reflects disease activity and is almost perfectly correlated with standard parameters such as PET/CT that are associated with refractoriness.
Keyphrases
- circulating tumor
- disease activity
- hodgkin lymphoma
- cell free
- circulating tumor cells
- systemic lupus erythematosus
- rheumatoid arthritis
- end stage renal disease
- pet ct
- rheumatoid arthritis patients
- chronic kidney disease
- ejection fraction
- ankylosing spondylitis
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- stem cells
- gene expression
- risk factors
- positron emission tomography